# Tumor-Associated Antigen-Specific Cytotoxic T-Lymphocytes for Multiple Myeloma

> **NCT02291848** · PHASE1 · RECRUITING · sponsor: **Baylor College of Medicine** · enrollment: 36 (estimated)

## Conditions studied

- Multiple Myeloma

## Interventions

- **BIOLOGICAL:** TAA-specific CTLs
- **BIOLOGICAL:** TAA-specific CTLs- fixed dose

## Key facts

- **NCT ID:** NCT02291848
- **Lead sponsor:** Baylor College of Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2015-04
- **Primary completion:** 2026-12
- **Final completion:** 2027-12-22
- **Target enrollment:** 36 (ESTIMATED)
- **Last updated:** 2026-02-25

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02291848

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02291848, "Tumor-Associated Antigen-Specific Cytotoxic T-Lymphocytes for Multiple Myeloma". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02291848. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*